$1.76
1.07%
Nasdaq, Tue, May 20 2025
ISIN
CA03835T2002
Symbol
APTO
Sector
Industry

Aptose Biosciences Inc. Stock price

$1.76
-0.41 18.75% 1M
-6.44 78.58% 6M
-5.00 74.03% YTD
-32.75 94.91% 1Y
-479.75 99.64% 3Y
-3,521.75 99.95% 5Y
-2,842.25 99.94% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.02 1.07%
ISIN
CA03835T2002
Symbol
APTO
Sector
Industry

Key metrics

Market capitalization $4.48m
Enterprise Value $8.72m
P/E (TTM) P/E ratio negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-21.96m
Cash position $4.74m
EPS (TTM) EPS $-27.62
Short interest 2.60%

Is Aptose Biosciences Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Aptose Biosciences Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Aptose Biosciences Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Aptose Biosciences Inc.:

Buy
100%

Financial data from Aptose Biosciences Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 0.41 0.41
7% 7%
-
-0.41 -0.41
7% 7%
-
- Selling and Administrative Expenses 21 21
66% 66%
-
- Research and Development Expense - -
-
-
-22 -22
55% 55%
-
- Depreciation and Amortization 0.41 0.41
7% 7%
-
EBIT (Operating Income) EBIT -22 -22
54% 54%
-
Net Profit -21 -21
55% 55%
-

In millions USD.

Don't miss a Thing! We will send you all news about Aptose Biosciences Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aptose Biosciences Inc. Stock News

Neutral
GlobeNewsWire
27 days ago
SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), announces that effective on April 15, 2025, KPMG LLP, the current independent registered public a...
Neutral
GlobeNewsWire
28 days ago
SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced that the Aptose management team will participate in the 2025 Bloom Burton & Co. ...
Neutral
GlobeNewsWire
about 2 months ago
Tuspetinib Triple Drug Frontline Therapy Advancing in TUSCANY Clinical Trial Results to Date Highlight TUS Potential as an Ideal Third Drug to Include in AML Triplet Therapy Aptose Signs Debt Conversion Agreement with Hanmi SAN DIEGO and TORONTO, March 28, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology c...
More Aptose Biosciences Inc. News

Company Profile

Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.

Head office Canada
CEO William Rice
Employees 13
Founded 1986
Website www.aptose.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today